These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 24684593)
1. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Beswick L; Friedman AB; Sparrow MP Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593 [TBL] [Abstract][Full Text] [Related]
2. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Gearry RB; Barclay ML J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561 [TBL] [Abstract][Full Text] [Related]
3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Kwan LY; Devlin SM; Mirocha JM; Papadakis KA Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898 [TBL] [Abstract][Full Text] [Related]
4. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease. Simsek M; Meijer B; Mulder CJJ; van Bodegraven AA; de Boer NKH Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228 [TBL] [Abstract][Full Text] [Related]
5. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098 [TBL] [Abstract][Full Text] [Related]
7. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214 [TBL] [Abstract][Full Text] [Related]
9. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond. Fong SC; Blaker PA; Arenas-Hernandez M; Marinaki AM; Sanderson JD Biomark Med; 2015; 9(1):51-65. PubMed ID: 25605455 [TBL] [Abstract][Full Text] [Related]
10. [Optimized thiopurine treatment in chronic inflammatory bowel disease]. Kiszka-Kanowitz M; Theede K; Nielsen AM Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625 [TBL] [Abstract][Full Text] [Related]
11. Thiopurine therapy in inflammatory bowel disease. Ha C; Dassopoulos T Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143 [TBL] [Abstract][Full Text] [Related]
12. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients. Nguyen TV; Nguyen TM; Lachaux A; Boulieu R J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979 [TBL] [Abstract][Full Text] [Related]
14. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Seidman EG Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587 [TBL] [Abstract][Full Text] [Related]
15. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA; Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097 [TBL] [Abstract][Full Text] [Related]
16. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Kennedy NA; Asser TL; Mountifield RE; Doogue MP; Andrews JM; Bampton PA Intern Med J; 2013 Mar; 43(3):278-86. PubMed ID: 22946880 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300 [TBL] [Abstract][Full Text] [Related]
18. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. de Boer YS; van Gerven NM; de Boer NK; Mulder CJ; Bouma G; van Nieuwkerk CM Aliment Pharmacol Ther; 2013 Mar; 37(6):640-6. PubMed ID: 23347359 [TBL] [Abstract][Full Text] [Related]